Elsevier

Biological Psychiatry

Volume 54, Issue 8, 15 October 2003, Pages 806-817
Biological Psychiatry

Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression

https://doi.org/10.1016/S0006-3223(02)01971-6Get rights and content

Abstract

Background

Maintenance treatment to prevent recurrences is recommended for chronic forms of major depressive disorder (MDD), but few studies have examined maintenance efficacy of antidepressants with chronic MDD. This randomized, placebo-controlled study of the efficacy and safety of nefazodone in preventing recurrence was conducted for patients with chronic MDD.

Methods

A total of 165 outpatients with chronic, nonpsychotic MDD, MDD plus dysthymic disorder (“double-depression”), or recurrent MDD with incomplete inter-episode recovery, who achieved and maintained a clinical response during acute and continuation treatment with either nefazodone alone or nefazodone combined with psychotherapy, were randomized to 52 weeks of double-blind nefazodone (maximum dose 600 mg/day) or placebo. The occurrence of major depressive episodes during maintenance treatment was assessed with the 24-item Hamilton Rating Scale for Depression, a DSM-IV MDD checklist, and a blinded review of symptom exacerbations by a consensus committee of research clinicians.

Results

Application of a competing-risk model that estimated the conditional probability of recurrence among those patients remaining on active therapy revealed a significant (p = .043) difference between nefazodone (n = 76) and placebo (n = 74) when the latter part of the 1-year maintenance period was emphasized. At the end of 1 year, the conditional probability of recurrence was 30.3% for nefazodone-treated patients, compared with 47.5% for placebo-treated patients. Prior concomitant psychotherapy during acute/continuation treatment, although enhancing the initial response, was not associated with lower recurrence rates. Discontinuations due to adverse events were relatively low for both nefazodone (5.3%) and placebo (4.8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%).

Conclusions

Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD.

Introduction

Epidemiologic studies suggest that approximately 17% of individuals will have an episode of major depressive disorder (MDD) in their lifetime (Kessler et al 1994). The extensive impairments in occupational and social functioning Hays et al 1995, Wells et al 1992 due to MDD have led to its identification as the most disabling illness in the developed countries by the World Health Organization (Murray and Lopez 1997). Chronic depressions account for much of the disability associated with MDD. Compared with nonchronic depression, chronic depression is associated with even greater impairments in psychosocial and work functioning Hays et al 1995, Miller et al 1998, Wells et al 1992, higher health care utilization (Howland 1993), and more frequent suicide attempts and hospitalization (Klein et al 1998). At any given time, at least 3% of the U.S. population has some form of chronic depression Kessler et al 1994, Weissman et al 1988.

Because of the chronic and recurrent nature of MDD, psychopharmacologic treatment has evolved to include an acute phase that aims to achieve a clinically significant reduction of symptoms, a continuation phase (4–9 months) to prevent a relapse of the index episode, and, in some cases, a maintenance phase (1 year or more) designed to prevent new episodes (Kupfer 1991). Continuation treatment is recommended for all cases of MDD (Depression Guideline Panel 1993), based on data showing a 25% relapse rate within 2 months of discontinuation of acute antidepressant treatment (Maj et al 1992) and numerous controlled continuation treatment trials demonstrating substantially lower relapse rates for active drug compared with placebo Coppen et al 1978, Doogan and Caillard 1992, Feiger et al 1999, Mindham et al 1973, Montgomery and Dunbar 1993, Montgomery et al 1988, Thase et al 2001.

Maintenance treatment has been recommended for individuals with a high likelihood of recurrence of MDD, including those with chronic forms of MDD (Depression Guideline Panel 1993). Several studies have demonstrated prophylactic efficacy of maintenance antidepressant therapy for patients with a history of previous episodes of MDD Frank et al 1990, Hochstrasser et al 2001, Montgomery and Dunbar 1993, Montgomery et al 1988, Prien et al 1984, Versiani et al 1999 and with dysthymia (Kocsis et al 1996), but only one study (Keller et al 1998) has demonstrated maintenance phase prophylactic efficacy of an antidepressant for patients with chronic forms of MDD.

Psychotherapy has also been examined for the prevention of relapse and recurrence of MDD. Short-term (acute phase only) cognitive therapy (Beck et al 1979) has reduced relapse relative to discontinued medication Blackburn et al 1986, Evans et al 1992, Kovacs et al 1981, and continuation cognitive therapy has reduced relapse relative to short-term cognitive therapy without continuation treatment. For patients with residual depressive symptoms after pharmacotherapy, cognitive therapy has been found to reduce recurrence rates relative to maintenance medication only (Paykel et al 1999) and treatment-as-usual (Teasdale et al 2000). The role of acute or continuation psychotherapy (with or without medication) in preventing recurrences during maintenance treatment has not been examined for patients with chronic forms of MDD.

We recently reported (Keller et al 2000) the acute-phase, 12-week outcomes of a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy (CBASP; McCullough 2000), and their combination in the treatment of chronic forms of MDD. Within the intent-to-treat sample, combined nefazodone and psychotherapy resulted in significantly greater acute-phase treatment response rates (73%) when compared with nefazodone alone (48%) and psychotherapy alone (48%). The gains made during the acute phase were generally maintained and consolidated during the continuation phase (Kocsis et al, unpublished data).

This article reports on results of the maintenance phase of this study, specifically a placebo-controlled examination of nefazodone as a maintenance treatment for patients with chronic forms of MDD who had achieved a clinical response over the course of acute and continuation treatment with either nefazodone or the combination of nefazodone and psychotherapy. Our primary hypothesis was that nefazodone would be superior to placebo in preventing recurrences during maintenance treatment. Secondarily, we hypothesized that prior combined treatment (during acute and continuation phases) would be associated with a lower recurrence rate during maintenance treatment, compared with prior treatment with nefazodone alone.

In conducting this trial, we encountered a methodological problem that may increasingly be an issue in long-term treatment studies for MDD. The growing awareness of the general public of treatment options for MDD, and the success of these treatments, may make it increasingly difficult to retain patients assigned to placebo in a prevention study. Particularly for patients with chronic or recurrent depression, sustained improvement in depressive symptoms provides a strong motivation for preferring to remain on active treatment. Patients randomly assigned to placebo may be inclined to discontinue treatment if there is any evidence (e.g., lack of medication side effects or re-emergence of one or two salient depressive symptoms) that they are no longer on active, previously successful treatment.

To address this issue, we applied a “competing risk” analytic strategy David and Moeschberger 1978, Gooley et al 1999, Prentice et al 1978 that has been applied to the study of other medical disorders in which, for example, risk for other causes of death “competes” with risk for death from the target illness under study. Recent examples employing such competing risk analysis include studies of the following: durability of aortic pericardial bioprosthesis (Banbury et al 2001); risk factors for sudden infant death syndrome (Pollack and Frohna 2001); incidence rates of opportunistic infections in acquired immune deficiency syndrome patients (Yan et al 2000); the probability of dying from prostate cancer given tumor histology and age of diagnosis (Albertsen et al 1998); and incidence of Alzheimer’s disease in the Framingham study (Beiser et al 2000). In the current context, the competing risk approach allows the risk for recurrence to be examined adjusting for the “competing risk” of study discontinuation for reasons other than recurrence.

Section snippets

Methods and materials

The study rationale and methods, detailed elsewhere (Keller et al 2000), are briefly summarized here.

Patient characteristics

Patient disposition leading up to and including the maintenance phase is given in Figure 1. Two hundred sixty-nine patients who responded to either nefazodone alone or combined treatment during the acute phase were subsequently enrolled in the continuation phase. Of these, 165 maintained their response and elected to participate in the maintenance phase. Safety analyses were conducted on these 165 patients. The sample evaluated for efficacy was 160 patients (n = 76 in nefazodone; n = 84 in

Discussion

The results of this multicenter, placebo-controlled maintenance trial suggest that nefazodone may protect against the recurrence of MDD in patients with chronic depression. At the end of the 1-year maintenance phase, the conditional probability of recurrence was 30.3% for nefazodone-treated patients compared with 47.5% for placebo-treated patients. This finding, however, was achieved in the context of a competing risks data analytic approach that focused on recurrences of new episodes of MDD by

Acknowledgements

This work was supported by grants from Bristol-Myers Squibb, Inc.

References (56)

  • H.A. David et al.

    The Theory of Competing Risks

    (1978)
  • Clinical Practice Guideline. Number 5Depression in Primary Care, Volume 2. Treatment of Major Depression

    (1993)
  • S.C. Dilsaver et al.

    Antidepressant withdrawal phenomena

    Biol Psychiatry

    (1984)
  • D.P. Doogan et al.

    Sertraline in the prevention of depression

    Br J Psychiatry

    (1992)
  • M.D. Evans et al.

    Differential relapse following cognitive therapy, pharmacotherapy, and combined cognitive-pharmacotherapy for depression

    Arch Gen Psychiatry

    (1992)
  • G.A. Fava et al.

    Prevention of recurrent depression with cognitive behavioral therapyPreliminary findings

    Arch Gen Psychiatry

    (1988)
  • J. Fawcett et al.

    Clinical management—imipramine/placebo administration manual

    Psychopharmacology Bull

    (1987)
  • A.D. Feiger et al.

    Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

    Int Clin Psychopharmacology

    (1999)
  • E. Frank et al.

    Three-year outcomes for maintenance therapies in recurrent depression

    Arch Gen Psychiatry

    (1990)
  • E. Frank et al.

    Conceptualization and rationale for consensus definitions of terms in major depressive disorderRemission, recovery, relapse, and recurrence

    Arch Gen Psychiatry

    (1991)
  • J.J. Gaynor et al.

    On the use of cause-specific failure and conditional failure probabilitiesExamples from clinical oncology data

    J Am Stat Association

    (1993)
  • T.A. Gooley et al.

    Estimation of failure probabilities in the presence of competing risksNew representations of old estimators

    Stat Med

    (1999)
  • M. Hamilton

    Development of a rating scale for primary depressive illness

    Br J Soc Clin Psychol

    (1967)
  • R.D. Hays et al.

    Functioning and well-being outcomes of patients with depression compared with chronic general medical illness

    Arch Gen Psychiatry

    (1995)
  • B. Hochstrasser et al.

    Prophylactic effect of citalopram in unipolar recurrent depression

    Br J Psychiatry

    (2001)
  • R.H. Howland

    Chronic depression

    Hosp Community Psychiatry

    (1993)
  • R.B. Jarrett et al.

    Is there a role for continuation phase cognitive therapy for depressed outpatients?

    J Consult Clin Psychol

    (1998)
  • M.B. Keller et al.

    Maintenance phase efficacy of sertraline for chronic depression. A randomized controlled trial

    JAMA

    (1998)
  • Cited by (0)

    View full text